Infosys, Zydus Lifesciences, Biocon, Godrej Properties, EMS Ltd, Cipla and Apollo Tyres among top stocks to watch today
Stocks to Watch: Infosys plans to train and certify 50,000 employees on NVIDIA AI technology to provide expertise to its customers across industries. Zydus on Wednesday said that it had received final approval from the USFDA for Clindamycin Phosphate Gel.
Stocks to Watch: At 07:29 AM, the GIFT Nifty was trading 48 points, or 0.24 per cent, lower at 19,857.5 levels, indicating a negative start to trading on Dalal Street on Thursday, September 21.
On Wednesday, domestic equities tumbled over a per cent amid weak global cues and heavy selling in HDFC Bank, and Reliance Industries (RIL). At close, the S&P BSE Sensex stood at 66,800.84, down 796 points, or 1.18 per cent, while the NSE's Nifty declined 231.90 points, or 1.15 per cent, to settle at 19,901.40.
That said, let's take a look at the top stocks that may remain in focus today.
Honor 90 Price In India: Instant Rs 3,000 discount, 12 months no-cost EMIs and much more - Check details
Animal vs Sam Bahadur Box Office Collection: Animal set to enter Rs 500 crore club, beat Sam Baadur on Day 5 | Check day-wise collection, OTT release date and more
Ayodhya Airport Update: Jyotiraditya Scindia meets AAI officials after inspecting Maryada Purushottam Shri Ram International Airport
IT company Infosys plans to train and certify 50,000 employees on NVIDIA AI technology to provide expertise to its customers across industries, the company said on Wednesday.
The development follows the expansion of collaboration between Infosys and chipset company NVIDIA to provide generative AI-based solutions to enterprises worldwide.
"Infosys plans to set up an NVIDIA Centre of Excellence, where it will train and certify 50,000 of its employees on NVIDIA AI technology to provide generative AI expertise to its vast network of customers across industries," Infosys and NVIDIA said in a joint statement.
The company's shares are slated to debut on bourses today.
In its regulatory filing, the company said that Bias and OTR tyres production at its manufacturing facility in Limda, Gujarat, has been stopped due to certain concerns amongst shop floor employees relating to the renewal of the long-term settlement agreement.
Biocon Biologics Ltd., a subsidiary of Biocon Ltd, has announced that the European Commission (EC) granted marketing authorization in the European Union (EU) for YESAFILI®, a biosimilar of Aflibercept.
The company's QIP opened on September 20. The floor price for the same has been fixed at Rs 1,133.99 apiece, which is a 3 per cent discount to the last closing price. The issue price for the same will be fixed on September 25 at the board meeting.
Fino Payments Bank
The bank has received complaints from clients and some merchants/distributors of Gujarat regarding the misappropriation of funds/ cheating and forgery.
Zydus Lifesciences Limited said on Wednesday that it had received final approval from the United States Food and Drug Administration (USFDA) for Clindamycin Phosphate Gel USP, 1% (USRLD: Cleocin T Gel, 1%). Clindamycin Phosphate Gel USP, 1%, is used to treat acne.
"The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad (India)," the company said in a filing. Clindamycin Phosphate Gel USP, 1%, had annual sales of $37 million in the United States.
Realty firm Godrej Properties said on Wednesday it had raised Rs 1,160 crore through the issue of non-convertible debentures on a private placement basis. In a regulatory filing, the company said the allotment committee of the Board of Directors approved the allotment of the non-convertible debentures (NCDs).
The software firm said on Wednesday that it had appointed Anurag Mantri as executive director, CFO, and chief operating officer of the company w.e.f. September 21, 2023.
"Mr. Anurag Mantri started his career with Nucleus Software in 1994. While working with Nucleus, Anurag has managed complex global and regional business transformation programs and cutting-edge digital transformation initiatives," the company said in its filing.
The company's wholly-owned subsidiary, InvaGen has received 5 inspectional observations in Form 483. USFDA conducted its inspection at the InvaGen manufacturing facility in Central Islip, Long Island, NY, USA, from September 11, 2023, to September 19, 2023.
The government may sell a 4.92 per cent stake in the company. The floor price for OFS has been fixed at around Rs 69 apiece, which is a 16 per cent discount to the current market price. Besides, the company will hold a board meeting on September 23 to consider fund-raising.
Shares of wires and cables manufacturer RR Kabel Ltd ended with a premium of nearly 16 per cent against the issue price of Rs 1,035 on the first day of trading on Wednesday.
RR Kabel became the first company to debut on the exchanges within two days of the issue closing. It became the first company to list in the T+2 timeline, the second working day after the issue closed on September 15. The stock is expected to hog the limelight today as well.
Central trade unions, including Bharatiya Mazdoor Sangh and the All India Trade Union Congress, have demanded the salaries of non-executive employees as per the latest wage pact from Coal India and threatened a three-day strike.
The trade unions have demanded that the salaries of non-executive employees of Coal India be given according to the National Coal Wage Agreement (NCWA) XI.
Aurobindo Pharma on Wednesday said the US health regulator had issued a Form 483 with one observation after inspecting the formulation production facility of its unit in Andhra Pradesh.
The US Food and Drug Administration (US FDA) inspected Unit IV of APL Healthcare Ltd., a wholly-owned subsidiary of the company, in Tirupati district of Andhra Pradesh from September 13–19, 2023, the Hyderabad-based drug major said in a regulatory filing.